Stock Financial Ratios, Dividends, Split History

XLRN / Acceleron Pharma Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,118.94
Enterprise Value ($M)2,058.82
Book Value ($M)353.78
Book Value / Share7.73
Price / Book6.02
NCAV ($M)284.04
NCAV / Share6.21
Price / NCAV7.49
Share Statistics
Common Shares Outstanding 45,419,061
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 45,261,175
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.30
Return on Assets (ROA)-0.44
Return on Equity (ROE)-0.48
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio23.20
Income Statement (mra) ($M)
Reimbursement Revenue12,940,000.00
Operating Income-109.98
Net Income-108.45
Earnings Per Share Basic-2.68
Earnings Per Share Diluted-2.68
Earnings Per Share Basic And Diluted-2.68
Cash Flow Statement (mra) ($M)
Cash From Operations-76.73
Cash from Investing-64.37
Cash from Financing-64.37
Identifiers and Descriptors
Central Index Key (CIK)1280600
Related CUSIPS
00434H908 000434H10 00434H958

Split History

Stock splits are used by Acceleron Pharma Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Your Daily Pharma Scoop: Zogenix Zooms, Zynerba's Changing Fortunes, AbbVie Proceeds

2018-07-15 seekingalpha
Discussion: Zogenix (ZGNX) announced positive result of a second Phase 3 clinical trial of its ZX008 (low-dose fenfluramine hydrochloride) in Dravet syndrome. The disease is a rare and severe form of epilepsy in children and young adults. Patients in the group under trial experienced a significant betterment, of 54.7% (compared to placebo) decrease in mean monthly convulsive seizures. Both the key secondary endpoints were also met by the trial results. (25-1)

Will Acceleron Pharma Momentum Continue After New FDA Nod?

2018-07-13 247wallst
Acceleron Pharma Inc. (NASDAQ: XLRN) shares reached a multiyear high last month after the company and Celgene Corp. (NASDAQ: CELG) announced positive late-stage trial results, but those shares dipped on Friday after the company provided an update from the U.S. Food and Drug Administration (FDA). (2-0)

Top Analyst Upgrades and Downgrades: AT&T, BlackRock, Broadcom, Diageo, Kinross Gold, United Rentals, Williams-Sonoma and More

2018-07-13 247wallst
Stocks were looking for direction on Friday, with mixed results in the major equity index futures this Friday the 13th. Investors have had less faith buying the dips in 2018 than in prior years. Many of those investors also have been concerned about how they want their investments positioned ahead of the midterm elections and into international trade concerns and for the longer-term into 2019 and beyond. (8-5)

Celgene Reports Positive Data on Tecentriq, Abraxane Study

2018-07-11 zacks
Celgene Corporation (CELG - Free Report) announced positive results from a late-stage study on oncology drug, Abraxane, in combination with Roche’s (RHHBY - Free Report) immuno-oncology drug, Tecentriq. (7-0)

Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish

2018-07-11 seekingalpha
Note: ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is when we covered it. (53-3)

CUSIP: 00434H108